CareDx, Inc. Q2 FY26 Results

Summary

CareDx, Inc. announced robust financial results for the second quarter ended June 30, 2026, with total revenue climbing 52% year-over-year to $132 million. This growth was primarily fueled by a 61% increase in Testing Services revenue, which reached $100 million. The company achieved a GAAP net income of $111 million, a significant turnaround from a net loss of $9 million in the same period last year, partly due to a $113 million gain from the sale of its Lab Products business. Adjusted EBITDA also saw a substantial rise to $25 million from $5 million year-over-year, demonstrating improved operational efficiency. Management expressed confidence in their strategy, raising full-year 2026 revenue guidance to $490 million-$500 million and Adjusted EBITDA guidance to $66 million-$78 million.

Key Highlights

1. 1

   CareDx, Inc. reported a significant 52% year-over-year increase in total revenue, reaching $132 million for the second quarter ended June 30, 2026.

2. 2

   Testing Services revenue surged by 61% year-over-year to $100 million, with testing services volume growing by 17% to approximately 58,000.

3. 3

   The company achieved a GAAP net income of $111 million in Q2 2026, a substantial improvement from a GAAP net loss of $9 million in the prior year's second quarter.

4. 4

   Adjusted EBITDA for the quarter dramatically increased to $25 million, up from $5 million in the second quarter of 2025, reflecting strong operational performance.

5. 5

   CareDx recognized a $113 million gain on the sale of its Lab Products business, which closed on June 30, 2026.

6. 6

   The company raised its full-year 2026 revenue guidance to a range of $490 million to $500 million.

7. 7

   Full-year 2026 Adjusted EBITDA guidance was also raised to a range of $66 million to $78 million.